A Randomized, Open-Label, Phase 3 Study of Nivolumab (BMS-936558) vs. Everolimus in Subjects With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma Who Have Received Prior Anti-Angiogenic Therapy
收藏DataCite Commons2025-11-25 更新2026-05-07 收录
下载链接：
https://search.vivli.org/doiLanding/studies/PR00011970/isLanding
下载链接
链接失效反馈官方服务：
资源简介：
The purpose of the study is to compare the clinical benefit, as measured by duration of overall survival, of Nivolumab vs. Everolimus in subjects with advanced or metastatic clear-cell renal cell carcinoma who have received prior anti-angiogenic therapy
提供机构：
Vivli
创建时间：
2025-11-24
